European Commission approves VELCADE®

Janssen-Cilag International NV (Janssen) has announced that the European Commission (EC) has approved the use of VELCADE® (bortezomib) as induction therapy (a first therapeutic option) in combination with dexamethasone (VD) or thalidomide and dexamethasone (VTD).
Source: Pharmacy Europe - Category: Drugs & Pharmacology Source Type: news